Three Houston companies are going into the semifinals of Cleantech.org's competition. Photo via Getty Images

Three Houston energy startups are in the running for the $100,000 cash prize in Cleantech.org's GS Beyond Energy Innovation Challenge.

Amperon Holdings, Cemvita Factory, and Veloce Energy are among the competition's 24 semifinalists, which were announced June 17. Five semifinalists will be chosen to pitch their concepts during a virtual event July 21, and then the winner of the $100,000 prize will be named.

"This is not like the cleantech sector was 10 years ago. Getting down to 24 [semifinalists] was hard. Getting down to five finalists will be extremely challenging," Neal Dikeman, chairman and founder of Cleantech.org and a partner at one of the prize sponsors, Houston-based Energy Transition Ventures, says in a news release.

Amperon, with an office in Houston and headquarters in New York City, is a semifinalist in the "digitization of energy" category. The company, founded in 2017, builds real-time electricity demand tools for utilities, energy retailers, grid operators, and institutional traders. So far, Amperon has raised $4.3 million in funding, according to Crunchbase.

Houston-based Cemvita, founded in 2017 by siblings Tara and Moji Karimi, is a semifinalist in the "new fuels" category. Its biotechnology transforms carbon dioxide emissions into sustainable chemicals and polymers. In a recent interview for the Houston Innovators Podcast, Moji Karimi explained how unprecedented his work is — and how ready for collaboration his team is.

"There weren't biotech companies working with oil and gas companies for this use case that we have now," Karimi says. "We're defining this new category for application of synthetic biology in heavy industries for decarbonization."

Veloce, with an office in Houston and headquarters in Los Angeles, is a semifinalist in the "e-mobility in cities" category. The company, founded in 2020, aims to make installation of electric vehicle charging stations cheaper and faster. Veloce is an inaugural member of Greentown Houston, an incubator for climate technology startups.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.